Axalbion Announces Positive Findings from Phase 2 Clinical Study in Chronic Cough with AX-8, a Novel TRPM8 Agonist
Axalbion, a clinical-stage biopharmaceutical company focused on developing novel medicines to treat cough, today announced positive results from a Phase 2 proof-of-concept study (AX8-003) with its transient receptor potential melastatin 8 (TRPM8) agonist, AX-8, in patients with refractory or unexplained chronic cough.
- Axalbion, a clinical-stage biopharmaceutical company focused on developing novel medicines to treat cough, today announced positive results from a Phase 2 proof-of-concept study (AX8-003) with its transient receptor potential melastatin 8 (TRPM8) agonist, AX-8, in patients with refractory or unexplained chronic cough.
- The Phase 2 trial was a randomized, double-blind, placebo-controlled, crossover study that evaluated the efficacy and safety of AX-8 in 51 patients with refractory or unexplained chronic cough.
- Reduction in cough frequency was seen across patients in the study irrespective of high/low baseline cough frequency, duration of coughing, age or sex.
- AX-8, a potent and selective transient receptor potential melastatin 8 (TRPM8) agonist, is in development for treatment of chronic cough.